mdi-book-open-variant Impressum mdi-help Hilfe / Anleitung mdi-printer Webseite ausdrucken mdi-bookmark Bookmark der Webseite speichern mdi-magnify Suche & Index Wirkstoffe mdi-sitemap Sitemap CliniPharm/CliniTox-Webserver mdi-home Startseite CliniPharm/CliniTox-Webserver mdi-email Beratungsdienst: Email / Post / Fax / Telefon

Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P & Cato AC
I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor.

EMBO J, 16(15): 4698-4707, 1997
ISSN: 0261-4189 The EMBO Journal (PubMed)

Abstract
I kappaB alpha is an inhibitor protein that prevents nuclear transport-and activation of the transcription factor NF-kappaB. In acute inflammation, NF-kappaB is activated and increases the expression of several pro-inflammatory cytokine and chemokine genes. Glucocorticoids counteract this process. It has been proposed that the glucocorticoid-dependent inhibition of NF-kappaB activity is mediated by increased synthesis of I kappaB alpha which should then sequester NF-kappaB in an inactive cytoplasmic form. Here, we show by the use of a mutant glucocorticoid receptor and steroidal ligands that hormone-induced I kappaB alpha synthesis and inhibition of NF-kappaB activity are separable biochemical processes. A dimerization-defective glucocorticoid receptor mutant that does not enhance the I kappaB alpha level is still able to repress NF-kappaB activity. Conversely, glucocorticoid analogues competent in enhancing I kappaB alpha synthesis do not repress NF-kappaB activity. These results demonstrate that increased synthesis of I kappaB alpha is neither required nor sufficient for the hormone-mediated downmodulation of NF-kappaB activity.

© 2021 - Institut für Veterinärpharmakologie und ‑toxikologie

Es kann keinerlei Haftung für Ansprüche übernommen werden, die aus dieser Webseite erwachsen könnten.